ArticlePhysics and imaging in radiation oncology2026
Raman spectroscopy and atomic force microscopy as tools to evaluate the radiobiological sensitivity of breast cancer cells at different therapeutic doses.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Radiotherapy is widely used as a treatment for patients with breast cancer (BC). In vitro irradiation of BC cells provides a strategy to investigate early cellular and molecular events induced by ionizing radiation. Characterizing structural and membrane responses may identify biomarkers of radiosensitivity, improving understanding of treatment effects and enabling patient specific optimization. In this work, Raman spectroscopy and atomic force microscopy (AFM) were applied in vitro to investigate mechanisms relevant to BC radiotherapy. Materials and methods: Breast cancer cell line MD Anderson-Metastatic Breast-231 (MDA-MB-231) was exposed to doses of 2, 4, and 10 Gy. Non-irradiated BC cells were used as control samples. Samples were incubated at 37 °C, 5% carbon dioxide (CO Results: Raman spectroscopy showed significantly increased intensities at 1250, 1455, and 1670 cm Conclusions: Raman spectroscopy and AFM demonstrate the capability to detect early radiation-induced chemical and surface alterations, suggesting potential utility for identifying biomarkers of radiotherapeutic response in breast cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.